Navigation Links
DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX'
Date:9/30/2009

PRINCETON, N.J., Sept. 30 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: SNGX), a late-stage biotechnology company, announced today that it has completed a corporate name change from DOR BioPharma, Inc. to Soligenix, Inc. (Soligenix or the Company). As a result of the name change, the Company's shares of common stock will immediately begin trading under the new ticker symbol "SNGX" as of today.

"We are pleased to announce the name change of our company to Soligenix," stated Christopher J. Schaber, Ph.D., President and CEO of Soligenix. "The name 'Soligenix' is derived in part from the Latin word 'Solis,' meaning sun. The name change heralds the new corporate stability and direction that we have worked hard to establish over the last several years."

Dr. Schaber continued, "We are also looking forward to the imminent initiation of our confirmatory Phase 3 clinical trial of orBec® in GI GVHD under a Special Protocol Assessment (SPA) with the FDA. In connection with the initiation of the trial, we expect to receive a $1 million milestone payment from Sigma-Tau in accordance with our collaboration agreement."

Soligenix's address and contact numbers will also remain the same. Soligenix's new web address is www.soligenix.com.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix), formally known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. Soligenix expects to begin a confirmatory Phase 3 clinical trial of orBec® for the treatment of a
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
2. Researchers prolong the plasma half-life of biopharmaceutical proteins
3. Emissary Capital Group Initiates Coverage on Sinobiopharma
4. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012
5. Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering
6. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
7. Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
8. Helix BioPharma Closes Private Placement
9. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
10. Helix BioPharma Announces $13.5 Million Private Placement
11. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary ... at the specialized Wolvega Horse Clinic. , Due to ... was ruptured 90% and her deep digital flexor tendon ... sentence for a horse. , The clinic has performed ... This revolutionary regenerative option for ruptured tendons has ...
(Date:9/19/2014)... simple. From crop yields to disease risks, the biological ... "complex traits." Just as for heightthe textbook example of ... disease are shaped by multiple genetic and environmental influences, ... track down such genes, geneticists typically mate two individuals ... and a small mouseand then study their descendents, looking ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... from Nicusa Capital urging BioClinica (Nasdaq: BIOC ) shareholders ... Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy: ... the Board BioClinica, Inc. 826 Newtown-Yardley Rd. Newtown, PA  18940 ... As of May 4, 2011, Nicusa owns 854,119 shares, ...
... Mass., May 4, 2011 InVivo Therapeutics (OTCBB: ... groundbreaking technologies for the treatment of spinal cord ... School of Medicine,s Miami Project to Cure Paralysis, ... today announced a strategic research collaboration for the ...
... , COLLEGE PARK, Md. It took nearly a decade ... their work identifying the anthrax strain used in the 2001 ... members of the high-powered science team have published the first ... of "microbial forensics" and gave bioterrorism investigators a way to ...
Cached Biology Technology:This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 2This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 3This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 4This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy 5InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 2InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 3InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries 4Now, the story can be told how scientists helped ID 'Amerithrax' 2Now, the story can be told how scientists helped ID 'Amerithrax' 3
(Date:9/21/2014)... dioxide emissions, the main contributor to global warming, are set ... of 40 billion tonnes. , The 2.5 per cent projected ... Carbon Project, which is co-led in the UK by researchers ... University of East Anglia and the College of Engineering, Mathematics ... comes ahead of the New York Climate Summit, where world ...
(Date:9/21/2014)... In recent years, new strains of bacteria have emerged ... these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, ... at least 23,000. Despite the urgent need for new ... antibiotics in the past decade. , MIT engineers have ... Using a gene-editing system that can disable any target ...
(Date:9/21/2014)... MA -- Shellfish such as mussels and barnacles secrete ... or ship hulls, even underwater. Inspired by these natural ... materials that could be used to repair ships or ... their new waterproof adhesives, the MIT researchers engineered bacteria ... mussel proteins as well as a bacterial protein found ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... Men with type 1 diabetes may be able ... tissue, say Georgetown University Medical Center (GUMC) researchers who ... Cell Biology 50th annual meeting in Philadelphia. Their laboratory ... human spermatogonial stem cells (SSCs) extracted from testicular tissue ...
... ANTONIO Do not delay treatment of breast cancer just ... Dr. med, of the German Breast Group. This suggestion ... treatment options on the infant. Loibl presented this data at ... Dec. 8-12, 2010. "At the time we started the ...
... the trail of some of the most economically damaging organisms ... water fungus that causes powdery mildew and the water molds ... mildew in cruciferous vegetables and other crops. , "We have ... Professor Sophien Kamoun, head of the Sainsbury Laboratory on the ...
Cached Biology News:'Grow your own transplant' may be possible for men with type 1 diabetes 2Unique needs and outcomes of pregnant women with breast cancer identified 2Gene hunters tackle crop diseases 2
... Ambions 96 well Magnetic-Ring Stand is ... 96 well U-bottom microplates. The stand has ... 96 well microtiter plate footprint. The use ... enables fast and easy magnetic separation. With ...
... from Thermus aquaticus expressed in E. coli; ... of 250 units enzyme/tube and Buffer I ... the same enzyme as AmpliTaq DNA Polymerase ... separation process to ensure that contaminating bacterial ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... is a versatile and easy-to use enzyme, ... GCpro Taq DNA Polymerase is prepared from ... containing the DNA polymerase I gene from ... processive 5'-3' DNA polymerase activity. Its inherent ...
Biology Products: